

[First Hit](#)

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

☐ [Generate Collection](#) [Print](#)

L3: Entry 1 of 3

File: DWPI

Jan 8, 1998

DERWENT-ACC-NO: 1998-064335

DERWENT-WEEK: 199929

COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Therapeutic composition containing epicatechin and/or theaflavin - and/or (gallate) derivatives, optionally as plant extract, useful as health food, dietary supplement or pharmaceutical, as antioxidant, etc.

PATENT-ASSIGNEE: VITASYN GMBH ENTWICKLUNG & VERTRIEB PHAR (VITAN)

PRIORITY-DATA: 1996DE-1027344 (July 1, 1996), 1996DE-2023606 (July 1, 1996)

[Search Selected](#) [Search ALL](#) [Clear](#)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<input type="checkbox"/> <u>DE 19627344 A1</u>	January 8, 1998		007	A61K031/35
<input type="checkbox"/> <u>DE 29623606 U1</u>	June 10, 1999		000	A61K035/78

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
DE 19627344A1	July 1, 1996	1996DE-1027344	
DE 29623606U1	July 1, 1996	1996DE-1027344	Application no.
DE 29623606U1	July 1, 1996	1996DE-2023606	

INT-CL (IPC): A23 L 1/29; A61 K 31/35; A61 K 35/78

ABSTRACTED-PUB-NO: DE 19627344A

BASIC-ABSTRACT:

A composition (I) contains (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin-3-gallate, (-)-epigallocatechin-3-gallate, theaflavin(TF-1), theaflavin monogallate A (TF-2A), theaflavin monogallate B (TF-2B) and/or theaflavin digallate (TF-3), obtained by extraction from Camellia sinensis L. or by synthesis, in the form of a complete drug, drug components, extracts, individual components, derivatives and/or mixtures.

USE - (I) is useful for the prevention or treatment of oxidative stress, toxic effects due to radical chain reaction damage to biological structures, tumours and their earlier stages, metastasis, radical damage in cytostatic chemotherapy, radical damage radiation therapy or chemotherapy, humoral or cellular immunity diseases (including autoimmune diseases, HIV and AIDS), inhibition of reverse transcriptase of HIV-1 and other HIV types, inflammatory diseases of all types, liver disease, infections (including infection with bacteria, virus, protozoa, virion, prion), arteriosclerosis, lipid metabolism disorders, hyperglycaemia, hypertension, diarrhoea and hypercholesterolaemia; as supportive therapy in weight



reduction (medical or cosmetic); for reduction of high serum triglycerides; for improvement of atherogenic index in patients at cardiovascular risk factors; to improve the antioxidant status of patients with renal insufficiency, especially in haemodialysis patients; for the prophylaxis and delaying of premature ageing in all tissues in living conditions associated with premature ageing; and for the prophylaxis of caries (all claimed). The treatment is useful in rheumatic conditions and cancer.

Dosage is 300-1200 mg per day. Administration is oral, enteral, parenteral, rectal, external, intramuscular, subcutaneous, vaginal, sublingual, nasal, buccal, dermal, or intracutaneous.

ABSTRACTED-PUB-NO: DE 19627344A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: B02 D13
CPI-CODES: B06-A01; B14-A02; B14-C03; D03-H01T2; D08-A05;

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)